GLYC
GlycoMimetics Inc
NASDAQ: GLYC · HEALTHCARE · BIOTECHNOLOGY
$0.16
+0.00% today
Updated 2026-04-30
Market cap
$10.13M
P/E ratio
—
P/S ratio
1,095.16x
EPS (TTM)
$-46.00
Dividend yield
—
52W range
$0 – $18
Volume
—
GlycoMimetics Inc (GLYC) Financial statements
SEC filings — annual and quarterly data.
Profit margin
0.00%
Operating margin
0.00%
ROE
-182.70%
ROA
-74.00%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2011 | $3.81M | $-6.11M | 100.00% | -159.54% | -160.29% |
| 2012 | $15.26M | $3.66M | 100.00% | 24.00% | 23.96% |
| 2013 | $3.99M | $-10.61M | 100.00% | -265.21% | -265.63% |
| 2014 | $15.03M | $-11.12M | 100.00% | -74.13% | -74.01% |
| 2015 | $20.07M | $-12.77M | 100.00% | -63.69% | -63.62% |
| 2016 | $18000.00 | $-31.81M | 100.00% | -177,300.00% | -176,722.22% |
| 2017 | $0.00 | $-33.28M | — | — | — |
| 2018 | $0.00 | $-48.27M | — | — | — |
| 2019 | $9.00M | $-54.12M | -9.99% | -682.10% | -601.29% |
| 2020 | $10.16M | $-50.27M | 100.00% | -506.83% | -494.68% |
| 2021 | $1.16M | $-63.14M | 100.00% | -5,469.57% | -5,443.31% |
| 2022 | $74925.00 | $-93.33M | 100.00% | -63,267.27% | -124,562.69% |
| 2023 | $10000.00 | $-36.90M | 100.00% | -392,752.93% | -368,994.20% |
| 2024 | $0.00 | $-37.88M | — | — | — |